The FDA has eliminated the Risk Evaluation and Mitigation Strategies (REMS) previously required for six approved CAR T cell therapies targeting BCMA and CD19 antigens, marking a significant shift in regulatory approach. The move reflects confidence in the hematology community's experience managing cytokine release syndrome and neurotoxicity associated with these treatments. Leaders from Bristol Myers Squibb and the FDA's Center for Biologics Evaluation and Research emphasize this change will expedite patient access and ease provider burden. Analysts and cell therapy stakeholders view this as a positive development that could accelerate the adoption of CAR T treatments in community healthcare settings, while also shortening post-treatment monitoring requirements.